Dr. Ross on Biomarker Research Development in Liver Metastasis

Merrick I. Ross, MD
Published: Wednesday, Oct 11, 2017



Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastases.

The most important unmet challenge need in the treatment of these patients is better biomarkers, states Ross. Having biomarkers would allow physicians to know which patients will benefit from immunotherapy regimens.

Additionally, biomarkers will help determine who will develop a resistance to immunotherapy so alternative therapies can be identified for the patient, explains Ross.
 


Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses biomarker research development for patients with liver metastases.

The most important unmet challenge need in the treatment of these patients is better biomarkers, states Ross. Having biomarkers would allow physicians to know which patients will benefit from immunotherapy regimens.

Additionally, biomarkers will help determine who will develop a resistance to immunotherapy so alternative therapies can be identified for the patient, explains Ross.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x